Pharmacogenomic approaches that may guide preeclampsia therapy

dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:28:48Z
dc.date.available2014-05-27T11:28:48Z
dc.date.created2014-05-27T11:28:48Z
dc.date.issued2013-04-01
dc.identifierPharmacogenomics, v. 14, n. 6, p. 591-593, 2013.
dc.identifier1462-2416
dc.identifier1744-8042
dc.identifierhttp://hdl.handle.net/11449/75024
dc.identifier10.2217/pgs.13.23
dc.identifierWOS:000317405300001
dc.identifier2-s2.0-84875973410
dc.languageeng
dc.relationPharmacogenomics
dc.relation2.302
dc.relation0,845
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectantihypertensive therapy
dc.subjectepigenetics
dc.subjectepistasis
dc.subjectpharmacogenomics
dc.subjectpreeclampsia
dc.subjectatorvastatin
dc.subjectendoglin
dc.subjecthydralazine
dc.subjectlabetalol
dc.subjectmethyldopa
dc.subjectnifedipine
dc.subjectnitric oxide
dc.subjectvasculotropin receptor 1
dc.subjectCACNA1A gene
dc.subjectCYP3A5 gene
dc.subjectdisease marker
dc.subjectDNA polymorphism
dc.subjecteNOS gene
dc.subjectFLT 1 gene
dc.subjectgene
dc.subjecthuman
dc.subjectMMP9 gene
dc.subjectpersonalized medicine
dc.subjectreview
dc.subjecttreatment outcome
dc.subjectVEGF gene
dc.subjectVEGFR 1 gene
dc.subjectVEGFR 2 gene
dc.titlePharmacogenomic approaches that may guide preeclampsia therapy
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución